RxDoctor Payments Data

Vanessa Ortiz

Family · Chicago, ILNPI 1205234879

Payments from drug & device makers

$338in general payments, 2019–2025

Across 20 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$141
  • Novartis$43
  • Medtronic$41
  • Amarin Pharma, Inc.$36
  • Sanofi-aventis U.S. LLC$27
  • Astellas Pharma US Inc$20
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$338100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$338 in reported general payments places this provider in the 50th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$7,584
Medicare patients
33
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol127$159,975
JardianceEmpagliflozin88$122,038
OzempicSemaglutide67$99,515
RybelsusSemaglutide55$97,925
Soliqua 100-33Insulin Glargine/Lixisenatide52$66,324
EliquisApixaban47$55,331
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$46,700
MyrbetriqMirabegron32$33,521
TrulicityDulaglutide19$29,802
LinzessLinaclotide11$17,977
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$11,377
Novolog FlexpenInsulin Aspart35$7,519
Atorvastatin Calcium937$6,095
SymbicortBudesonide/Formoterol Fumarate16$5,732
Incruse ElliptaUmeclidinium Bromide17$5,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$141$197,440122 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$27$66,32452 claims
Astellas Pharma US IncMyrbetriq$20$33,52132 claims
AbbVieLinzess$15$17,97711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,941 family providers in Illinois.

Other family in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →